Differentiation syndrome (DS) is associated with a higher risk of coagulopathy and hemorrhage, which can be seen in patients with APL undergoing induction therapy with all-trans retinoic acid (ATRA) and acute myeloid leukemia (AML) on IDH and FLT3 inhibitors. Here, FLT3 is linked to acute myeloid leukemia.